170 related articles for article (PubMed ID: 38584220)
21. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis.
Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L
Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150
[TBL] [Abstract][Full Text] [Related]
23. An N
Chu X; Wang W; Sun Z; Bao F; Feng L
Math Biosci Eng; 2022 Jan; 19(1):253-270. PubMed ID: 34902990
[No Abstract] [Full Text] [Related]
24. Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.
Liu TT; Li R; Huo C; Li JP; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2021; 9():682002. PubMed ID: 34409029
[TBL] [Abstract][Full Text] [Related]
25. A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
Wang X; Zhao C; Huang D; Liu Z; Liu M; Lin F; Lu Y; Jia J; Lin L; Lin X; Li H; Chen Z
Front Immunol; 2022; 13():923533. PubMed ID: 35860262
[TBL] [Abstract][Full Text] [Related]
26. Identification of metabolism-related gene signature in lung adenocarcinoma.
Wang N; Wang H
Medicine (Baltimore); 2023 Nov; 102(47):e36267. PubMed ID: 38013279
[TBL] [Abstract][Full Text] [Related]
27. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma.
Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C
Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818
[TBL] [Abstract][Full Text] [Related]
28. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
Chen G; Dong Z; Wu D; Chen Y
J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
[TBL] [Abstract][Full Text] [Related]
29. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
30. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
31. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
32. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
33. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
34. A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma.
Li X; Xu C; Min Y; Zhai Z; Zhu Y
Clin Respir J; 2023 Dec; 17(12):1349-1360. PubMed ID: 38071755
[TBL] [Abstract][Full Text] [Related]
35. Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma.
Shang S; Wang MZ; Xing Z; He N; Li S
Front Immunol; 2022; 13():1024925. PubMed ID: 36505423
[TBL] [Abstract][Full Text] [Related]
36. Predictions of the dysregulated competing endogenous RNA signature involved in the progression of human lung adenocarcinoma.
Yang D; He Y; Wu B; Liu R; Wang N; Wang T; Luo Y; Li Y; Liu Y
Cancer Biomark; 2020; 29(3):399-416. PubMed ID: 32741804
[TBL] [Abstract][Full Text] [Related]
37. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
38. scRNA-seq revealed high stemness epithelial malignant cell clusters and prognostic models of lung adenocarcinoma.
Lin G; Gao Z; Wu S; Zheng J; Guo X; Zheng X; Chen R
Sci Rep; 2024 Feb; 14(1):3709. PubMed ID: 38355636
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
